ArticleNature2026
Erythropoietin receptor on cDC1s dictates immune tolerance.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities.Cancers · 2026Review
- Rethinking the origins and functions of adaptive immunity.Trends in immunology · 2026Review
- DEA hypothesis: disinhibition, enhancing recognition, and alerting the host are the three pillars of effective cancer immunotherapy.Journal for immunotherapy of cancer · 2026Review
- The DC1 conundrum: Do type I dendritic cells make or break allograft tolerance?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Review
- Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseases.Clinical kidney journal · 2026Review
- Tumor-derived DNA drives cancer-associated anemia by promoting reticulocyte clearance.Signal transduction and targeted therapy · 2026Article
- Protocol to annotate dendritic cell maturation types in vivo making use of lipid nanoparticle-based approaches.STAR protocols · 2026Article
- EPO Receptor Blockade in Dendritic Cells Enhances Antitumor CD8Cancer communications (London, England) · 2026Article
- Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression.Drugs in context · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
32 authors.
Xiangyue ZhangDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA. xiangyue@stanford.edu.ORCID http://orcid.org/0000-0003-0716-6815
Christopher S McGinnisDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.
Guotao YuDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-7430-3309
Sijie ChenDepartment of Genetics, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0003-4331-0773
Pingping ZhengDepartment of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, School of Medicine, Stanford University, Palo Alto, CA, USA.
Christian M SchürchDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-1792-1768
Kamir J Hiam-GalvezDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.
Nathan E Reticker-FlynnDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9963-039X
Wenhui GuoDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.
Winnie YaoDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0003-1159-5153
Jingtao QiuDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0003-0354-8357
Alexander MuselmanDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-5685-2646
Ian L LindeDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-6077-7466
John W HickeyDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Hao YanDepartment of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, School of Medicine, Stanford University, Palo Alto, CA, USA.
Victoria M TranDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Wenli QiuDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Delphine Brichart-VernosCIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS de Lyon, Lyon, France.
Toshihito HiraiDepartment of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, School of Medicine, Stanford University, Palo Alto, CA, USA.
Bo YuImmunEdge, Redwood City, CA, USA.
Xiuli AnLaboratory of Membrane Biology, New York Blood Center, New York, NY, USA.
Yanling XiaoDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-1755-1709
Helena PaidassiCIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS de Lyon, Lyon, France.ORCID http://orcid.org/0000-0001-9915-4365
Tiffany C ScharschmidtDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Michael AngeloDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0003-1531-5067
Dean SheppardDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6277-2036
Hongbo ChiDepartment of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9997-2496
Ansuman T SatpathyDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA.ORCID http://orcid.org/0000-0002-5167-537X
Sing Sing WayDivision of Infectious Diseases, Center for Inflammation and Tolerance, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0001-8948-1952
Bernard MalissenCentre d'Immunologie de Marseille-Luminy, Aix-Marseille Université, INSERM, CNRS, Marseille, France.ORCID http://orcid.org/0000-0003-1340-9342
Samuel StroberDepartment of Medicine (Immunology and Rheumatology), School of Medicine, Stanford University, Palo Alto, CA, USA.
Edgar G EnglemanDepartment of Pathology, School of Medicine, Stanford University, Palo Alto, CA, USA. edgareng@stanford.edu.ORCID http://orcid.org/0000-0002-2096-9279
Funding
Sickle cell bone marrow niche and regulation of platelet activation and erythropoiesisP01HL149626 · NHLBI · NEW YORK BLOOD CENTER · PI Karina Yazdanbakhsh · 2020 to 2026
$24.4MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MProject 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapyP01CA244114 · NCI · STANFORD UNIVERSITY · PI KIM, SEUNG K · 2021 to 2025
$10.0MSystems Biology of Tumor-Immune-Stromal Interactions in Metastatic ProgressionU54CA274511 · NCI · STANFORD UNIVERSITY · PI JOSEPH B SHRAGER · 2023 to 2026
$9.5McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MMicrobial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MTargeting Lymph Node Dependent Immune Tolerance in CancerR01CA251174 · NCI · STANFORD UNIVERSITY · PI EDGAR G. ENGLEMAN · 2021 to 2026
$3.2MNCI NIH HHS P01 CA244114NCI NIH HHS R01 CA251174NCI NIH HHS U54 CA274511NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS P01 HL149626NIAID NIH HHS 75N93022D00005NIAID NIH HHS T32 AI060537NIDA NIH HHS 75N95020D00005NIDDK NIH HHS P30 DK116074NIH HHS 75N93023D00005NIH HHS 75N99020D00005
Abstract
Type 1 conventional dendritic cells (cDC1s) are unique in their efferocytosis
Indexed as
Dendritic CellsImmune ToleranceReceptors, ErythropoietinAnimalsErythropoietinFemaleForkhead Transcription FactorsGraft RejectionLymph NodesMaleMiceMice, Inbred C57BLSpleenT-Lymphocytes, RegulatoryErythropoietinForkhead Transcription FactorsFoxp3 protein, mouseReceptors, Erythropoietin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.